Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma

NCT02623127 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT02623127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02623127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2015
Completion date
October 31, 2018
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thymic carcinoma